SBSibel Bolukcu

Sibel Bolukcu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sibel Bolukcu has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cancer prevalence and prognosis among individuals living with HIV and AIDS in Turkey: Multicenter BUHASDER study

    by Özlem Güler, Sıla Akhan, Atahan Çağatay, Ayşe Batırel, Elif Sargın Altunok, Sibel Bolukçu, Hülya Özkan Özdemir, Emine İlAy Duman, Müge Toygar Deniz, Derya Özyiğitoğlu, et al.

    Background: This multicentre study evaluated the prevalence, distribution, and risk factors of cancer among people living with HIV (PLWH) in Turkey over two decades. Mortality rates and factors were also investigated. Methods: This retrospective cohort study included 154 adults diagnosed with cancer and HIV between 2008 and 2024. Data were collected from the medical records. The demographics, clinical characteristics, cancer types, treatments, and outcomes were evaluated. The risk factors for ADCs and mortality were defined using multivariate logistic regression and Cox regression. The estimated survival time was determined using Kaplan-Meier analysis. Results: Among 8708 PLWH, cancer prevalence was 1.8% (95% CI:1.5-2). ADCs (66.9%) were twice as frequent as NADCs (33.1%). Most prevalent cancers were non-Hodgkin lymphoma (35.1%), Kaposi sarcoma (29.9%), and lung cancer (7.8%). Age ≤54 years, CD4 + T lymphocyte count ≤94/mm 3 , and HHV-8 co-infection were risk factors for ADCs. Mortality rate was 32%. Non-Hodgkin lymphoma and CD4 + T lymphocyte count ≤232/mm 3 at treatment completion predicted mortality. The 3-years overall survival rate was 67.6%. Conclusions: This study offers insights into cancer burden among PLWH in Turkey. High rates of ADCs and mortality highlight the importance of early HIV diagnosis and antiretroviral therapy access to reduce cancer burden in this population.

  • Open Access

    COVID‐19 Incidence and Factors Influencing Infection Risk Among People Living With HIV in Türkiye: Is Current Issue the Vaccine Hesitancy‐Opposition?

    by Asuman Inan, Orcun Barkay, Arda Karapınar, Fatma Yılmaz-Karadag, Selman Aktas, Sibel Bolukcu

    Introduction: As the Coronavirus Disease‐2019 (COVID‐19) pandemic intersects with the ongoing Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) crisis, concerns have emerged regarding the susceptibility of people living with HIV/AIDS (PLWH) to severe outcomes from COVID‐19. Despite global efforts to understand the interplay between HIV/AIDS and COVID‐19, research on this issue remains limited in Türkiye. This study investigates the incidence of COVID‐19 among PLWH in Türkiye and factors influencing infection risk. Materials and Methods: An online survey, conducted from April to June 2023, assessed COVID‐19 frequency and risk factors among PLWH aged 18 years and older in Türkiye. Demographic data such as age, gender, educational background, underlying health conditions, vaccination status, and COVID‐19 infection history were collected from individuals who voluntarily participated. Results: A total of 354 PLWH from 38 cities in Türkiye participated in the study. The median age was 35.8 (range 18–76); 78% were male and 65.5% were university graduates. The rate of experienced COVID‐19 among PLWH was 44.6%. Logistic regression analysis revealed that vaccinated individuals had an 84% lower risk of contracting COVID‐19 among PLWH. In sum, 80 participants were not vaccinated in this study; of them, 27.5% identified as vaccine opponents and 25% expressed vaccine hesitancy. Discussion: These findings suggest that vaccination status is the key determinant of COVID‐19 susceptibility among young and well‐educated PLWH in Türkiye. The notable level of vaccine hesitancy and opposition of PLWH highlights the need for public health initiatives aimed at addressing misinformation and enhancing vaccine confidence. Conclusion: This study underscores the urgent need to address vaccine hesitancy and vaccine opposition among educated PLWH in Türkiye. Amid evolving SARS‐CoV‐2 variants, vaccination remains paramount in mitigating COVID‐19 risks among PLWH. Further research should delve deeper into demographic‐specific vaccine concerns to optimize public health strategies and meet the unique needs of PLWH communities.


  • Open Access

    Correction to: Investigation of Factors Affecting IgG Antibody Response in COVID-19 Cases

    by Ayse Betul Uslu-Ersoz, Meliha Meric Koc, Sibel Bolukcu, Bilge Sumbul

    CORRECTION NOTE The original version of this article, unfortunately, contained a mistake. 4h author name (Bilge Sümbül) is missing in the published version. The original article has been corrected. Corrected article: https://doi.org/10.36519/kd.2024.4781

  • Open Access

    Investigation of Factors Affecting IgG Antibody Response in COVID-19 Cases

    by Ayse Betul Uslu-Ersoz, Meliha Meric Koc, Sibel Bolukcu

    Objective: His study aimed to evaluate the factors influencing antibody titers and duration of antibody positivity against SARS-CoV-2 in COVID-19 patients followed for a year. Methods: Adult patients diagnosed with COVID-19 between March and August 2020 were included. Patient data, including age, gender, body mass index (BMI), Charlson comorbidity index (CCI), and clinical severity scores, were recorded. Patients were evaluated four times, and quantitative antibody titers were measured. Results: 53.1% of 177 patients were male, with a median age of 47 (IQR=33.5-55). 39.5% had additional comorbidities. Based on clinical severity, 33.3% were mild, 46.9% were moderate, and 19.8% were severe cases. The median intervals at visits were 56. 92, 193, and 371 days. Antibody positivity rates decreased, with 88.7%, 80.8%, 45.9%, and 21.4% at each visit. Median SARS-CoV-2 anti-N IgG titers decreased, particularly at the third visit (p<0.0001). Significant correlations were found between anti-N IgG titers and disease severity. Multivariate analysis showed that as disease severity increased, the probability of antibody positivity at the first and third visits increased approximately 3 to 6 times. Age and CCI score were also independent variables affecting antibody positivity. Conclusion: We observed a significant decrease in anti-N IgG antibody titers, especially after six months, and a considerable decline within one year. Disease severity was the most significant factor affecting antibody positivity, followed by age and CCI score. The study suggests further research to understand the duration of SARS-CoV-2-induced antibodies, seropositivity, and protective immunity.

  • Open Access

    Factors Influencing HIV Infection in Children Born to HIV-Infected Mothers in Turkey

    by Esra Zerdali, Bilgül Mete, Özlem Altuntaş Aydın, Alper Gündüz, İnci Yılmaz Nakir, Sibel Bolukçu, Hayat Kumbasar Karaosmanoğlu, Dilek Yıldız Sevgi, Meliha Meriç Koç, Fehmi Tabak

    Background: Human immunodeficiency virus (HIV) is still a challenge for children. About 15 to 45% of the HIV positive pregnant women can transmit the virus to their children during pregnancy, delivery and/or breastfeeding. The risk of transmission can be decreased my several measures.Aims: To identify factors associated with HIV infection in children born to HIV-infected mothers.Study Design: A multi-center retrospective cohort study.Methods: A ten-year retrospective cohort study in five dedicated HIV centers was conducted. The 325 women in our cohort were between the ages of 18 and 45. During the study period, 44 (13.5%) of thesewomen gave birth and 51 babies were born. Of the 51 infants, 7 (13.7%) were HIV/AIDS positive.Results: Among the factors studied, breastfeeding, having a HIV positive sibling and being on antiretroviral treatment during pregnancy and detectable HIV-RNA during delivery were found statistically significant. A multivariable logistic regression analysis showed that being on antiretroviral treatment during pregnancy is the most important predictor of mother-to-child transmission. Conclusion: Mother-to-child transmission appears to be an important route of HIV transmission in Turkey. Lack of antiretroviral treatment during pregnancy appears to be a key factor in transmission.


  • Efficacy of Tocilizumab in Patients with Moderate and Severe COVID-19: A Retrospective Cohort Study of Single Center

    by Sibel Bölükçü, Dilara Karakuş, Gülay Okay, Yasemin Akkoyunlu, Bilge Sümbül, Bülent Durdu, Meliha Meriç Koç, Turan Aslan


  • Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls

    by Ali Mert, Haluk Vahaboğlu, Ferhat Arslan, Ayşe Batirel, Kemal Tolga Saraçoğlu, Aliye Bastug, Atahan Çağatay, İlIm Irmak, Gülçin Telli Dizman, İhSan Ertenli, et al.

    Coronavirus disease-2019 (COVID-19) associated pneumonia may progress into acute respiratory distress syndrome (ARDS). Some patients develop features of macrophage activation syndrome (MAS). Elevated levels of IL-6 were reported to be associated with severe disease, and anti-IL-6R tocilizumab has been shown to be effective in some patients. This retrospective multicenter case–control study aimed to evaluate the efficacy of tocilizumab in hospitalized COVID-19 patients, who received standard of care with or without tocilizumab. Primary outcome was the progression to intubation or death. PSMATCH (SAS) procedure was used to achieve exact propensity score (PS) matching. Data from 1289 patients were collected, and study population was reduced to 1073 based on inclusion–exclusion criteria. The composite outcome was observed more frequently in tocilizumab-users, but there was a significant imbalance between arms in all critical parameters. Primary analyses were carried out in 348 patients (174 in each arm) after exact PS matching according to gender, ferritin, and procalcitonin. Logistic regression models revealed that tocilizumab significantly reduced the intubation or death (OR 0.40, p = 0.0017). When intubation is considered alone, tocilizumab-users had > 60% reduction in odds of intubation. Multiple imputation approach, which increased the size of the matched patients up to 506, provided no significant difference between arms despite a similar trend for intubation alone group. Analysis of this retrospective cohort showed more frequent intubation or death in tocilizumab-users, but PS-matched analyses revealed significant results for supporting tocilizumab use overall in a subset of patients matched according to gender, ferritin and procalcitonin levels.


  • The effects of polypharmacy, nutritional and functional status on the progression of COVID-19 in older adults

    by Asiye Bahar Kaçmaz, Pınar Soysal, Semen Gökçe Tan, Bülent Durdu, Yasemin Akkoyunlu, Hamza Ogün, Fatmanur Karaköse-Okyaltırık, Sibel Bölükcü, Gülay Okay, Bilge Sümbül, et al.

    Objective: We aimed to evaluate the effects of nutritional factors, dependence in daily life activities, and polypharmacy on the length of hospitalization, clinical prognosis and mortality among hospitalized older COVID-19 patients. Materials and Methods: The charts of hospitalized COVID-19 patients older than 60 years old were reviewed retrospectively. We obtained findings on admission, comorbidities and the number of drugs used. The Mini Nutritional Assessment (MNA), the Barthel Index for Activities of Daily Living (BADL) and the Lawton Instrumental Activities of Daily Living (IADL) Scale were used to analyze the findings. Results: Out of the 73 patients, 39 were female and the mean age was 69.65 ± 7.39 years. Fourteen (19.2%) patients were transferred to the intensive care unit, and nine (12.3%) of them died. After adjustment for age, the number of respiration at the first admission was significantly higher (p=0.001), and BADL, IADL scores and oxygen saturations were significantly lower (p=0.00, p=0.001) in the patients transferred to the intensive care unit compared to the patients discharged. There was no association between the length of hospitalization and age, the number of drugs, BADL and IADL scores, but there was a significant negative correlation between the length of hospitalization (r: -0.310), MNA score (r: -0.275) and daily protein intake (p=0.008). No association between polypharmacy and clinical progression of COVID-19 was detected (p=0.109). Conclusion: Decrease in MNA scores and daily protein intake in older COVID-19 patients were associated with prolonged hospitalization. Functional dependence was associated with the need for intensive care and mortality. Keywords: COVID-19, polypharmacy, nutrition, activities of daily living, mortality

  • Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data

    by Fehmi Tabak, Esra Zerdali, Ozlem Altuntaş, Alper Gunduz, Sibel Bolukcu, Bilgul Mete, Inci Y Nakir, Hayat Kumbasar Karaosmanoglu, Dilek S Yildiz, Meliha Meric Koc, et al.

    Objectives: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a recommended and widely used regimen for HIV infection. In this study, we aimed to determine the efficacy and safety of E/C/F/TAF in people living with HIV (PLWH), who are either treatment-naïve or switched from any tenofovir disoproxil fumarate-containing regimen. For switched patients, we aimed to determine the impact of switching from tenofovir disoproxil fumarate (TDF) to TAF on lipid profile and kidney functions. Methods: ACTHIV-IST Study Group produced a database, and five dedicated HIV centres in Istanbul entered data of PLWH who switched from any TDF-containing regimen to E/C/F/TAF and treatment-naïve patients who were initiated with the E/C/F/TAF regimen between January 2017 and December 2019. Clinical findings, viral parameters, lipid studies, renal function tests, adverse events and adherence to the treatment were recorded in this prospective observational study. Results: The study included a total of 614 switched and treatment-naïve patients. Of 430 treatment-experienced patients, 89% (382) were men, and the mean age was 42 ± 12 years. Among them, 47% (181/382) self-identified as men who have sex with men (MSM). The median duration of HIV diagnosis was 54 ± 29 months. The median duration of E/C/F/TAF use was 20 ± 36 months and that of previous treatment was 23 ± 18 months. HIV-RNA was undetectable at baseline and month 12 in 84.1% (360/428) and 86.1% (328/381) of patients, respectively (p > 0.05). Mean CD4 counts were 708 ± 287 cells/µL and 802 ± 305 cells/µL at baseline and month 12, respectively (p < 0.001). Serum creatinine levels remained stable during the treatment period. Mean total cholesterol levels at baseline and month 12 were 172 and 211 mg/dL (p < 0.01), LDL-cholesterol 104 and 138 mg/dL (p < 0.01), HDL-cholesterol 39 and 49 mg/dL (p < 0.01) and triglycerides 134 and 174 mg/dL (p < 0.01), respectively. The treatment was generally well tolerated. Eight patients discontinued the therapy (drug interaction: 3; lost to follow-up: 1; pregnancy: 1; pulmonary tuberculosis: 1; side effect: 1; patient’s decision: 1). Of 184 treatment-naïve patients, 88% (162) were men, and the mean age was 36.5± 12 years. Among them, 50% (81/162) self-identified as MSM. The mean duration of HIV infection was 21.6 ± 17.1 months. The mean duration of E/C/F/TAF use was 16 ± 4 months. HIV-RNA was undetectable at baseline and month 12 in 1% and 89.1% of patients, respectively. Mean CD4 counts at baseline and month 12 were 469 ± 223 cells/µL and 740 ± 298 cells/µL, respectively. During the treatment period, creatinine levels remained stable. Total cholesterol, LDL-cholesterol, triglyceride and also HDL-cholesterol levels increased. Mean total cholesterol levels at baseline and month 12 were 167 and 211 mg/dL (p < 0.01), LDL-cholesterol 108 and 143 mg/dL (p < 0.01), HDL-cholesterol 41 and 47 mg/dL (p < 0.01) and triglycerides 136 and 172 mg/dL, respectively (p < 0.01). The treatment was generally well tolerated. Three patients discontinued the therapy (drug interaction: 1; non-responder: 1; patient’s decision: 1). Conclusion: Starting with or switching to E/C/F/TAF in PLWH effectively suppresses HIV infection, is associated with an increase in CD4 cell count and is well tolerated in a real-life setting. Renal functions remained stable during the treatment. E/C/F/TAF use was associated with an increase in LDL-cholesterol and triglyceride levels along with an increase in HDL-cholesterol levels.


  • COVID-19 and Influenza Coexistence

    by Ayşe Betül USLU ERSÖZ, Sibel Bolukçu, Nurgül Andi̇ç, Dilara Karakuş, Gülay Okay, Bilge Sümbül, Asiye Bahar Kaçmaz, Bülent Durdu, Yasemin Akkoyunlu, Meliha Meri̇ç Koç